- Home
- PLX vs STXS Comparison
PLX vs STXS Comparison
Compare PLX & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- STXS
- Stock Information
- Founded
- PLX 1993
- STXS 1990
- Country
- PLX United States
- STXS United States
- Employees
- PLX N/A
- STXS N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PLX Health Care
- STXS Health Care
- Exchange
- PLX Nasdaq
- STXS Nasdaq
- Market Cap
- PLX 127.4M
- STXS 151.3M
- IPO Year
- PLX 1998
- STXS 2004
- Fundamental
- Price
- PLX $1.54
- STXS $2.48
- Analyst Decision
- PLX Strong Buy
- STXS
- Analyst Count
- PLX 1
- STXS 0
- Target Price
- PLX $15.00
- STXS N/A
- AVG Volume (30 Days)
- PLX 498.6K
- STXS 712.8K
- Earning Date
- PLX 08-14-2025
- STXS 08-07-2025
- Dividend Yield
- PLX N/A
- STXS N/A
- EPS Growth
- PLX N/A
- STXS N/A
- EPS
- PLX 0.05
- STXS N/A
- Revenue
- PLX $59,764,000.00
- STXS $31,806,000.00
- Revenue This Year
- PLX $10.00
- STXS $29.03
- Revenue Next Year
- PLX $83.13
- STXS $44.05
- P/E Ratio
- PLX $32.18
- STXS N/A
- Revenue Growth
- PLX 0.18
- STXS 33.94
- 52 Week Low
- PLX $0.82
- STXS $1.54
- 52 Week High
- PLX $3.10
- STXS $2.72
- Technical
- Relative Strength Index (RSI)
- PLX 53.22
- STXS 59.23
- Support Level
- PLX $1.41
- STXS $2.18
- Resistance Level
- PLX $1.52
- STXS $2.67
- Average True Range (ATR)
- PLX 0.06
- STXS 0.14
- MACD
- PLX 0.01
- STXS -0.00
- Stochastic Oscillator
- PLX 56.52
- STXS 66.07
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.